Thalidomide-NH-CBP/p300 ligand 2

Target: Targets CBP and p300 bromodomain acetyltransferase paralogs for experimental targeted protein degradation studies.

Binding Site: Binds the CBP/p300 bromodomain acetyl-lysine pocket and cereblon ligand module to support productive ternary complex formation.

Mechanism of Action: Thalidomide-NH-CBP/p300 ligand 2 is designed for use in PROTAC or targeted protein degradation experiments directed toward CBP and p300 bromodomain acetyltransferase paralogs. The bifunctional molecule links a target-recognition element to cereblon, promoting proximity between the protein of interest and ubiquitination machinery. Productive ternary-complex formation can drive polyubiquitination and proteasome-dependent target depletion, allowing researchers to compare pharmacological inhibition with protein removal. It is suitable for evaluating degradation potency, kinetics, pathway selectivity, and downstream signaling consequences in engineered or disease-relevant cellular models.

• PROTAC-Mediated Epigenetic Regulation: Thalidomide-NH-CBP/p300 ligand 2 is utilized in research to selectively degrade CBP/p300, key epigenetic regulators. This enables the study of histone acetylation processes and their impact on gene expression, providing insights into transcriptional regulation and potential therapeutic targets in cancer and other diseases.

• Targeted Degradation of Coactivators: By facilitating the degradation of CBP/p300, this PROTAC compound aids in dissecting the roles of transcriptional coactivators in cellular processes. Researchers can explore the dynamic interactions between coactivators and transcription factors, advancing the understanding of cellular signaling pathways.

• Investigating Protein-Protein Interactions: This compound is instrumental in studying CBP/p300 interactions with various proteins. Through targeted degradation, scientists can elucidate complex interaction networks, providing a deeper understanding of cellular mechanisms and identifying novel intervention points for drug development.

• Chromatin Remodeling Studies: Thalidomide-NH-CBP/p300 ligand 2 serves as a valuable tool in examining chromatin remodeling events. By degrading CBP/p300, researchers can assess how alterations in chromatin structure influence gene accessibility and expression, contributing to the field of epigenetics and therapeutic innovation.